3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
46
Breast Neoplasms
9
Salivary Gland Neoplasms
2
Prostate Adenocarcinoma
2
Neoplasm Metastasis
2
Breast Neoplasms, Male
2
Stage I Prostate Adenocarcinoma AJCC v7
1
Sexual Dysfunctions, Psychological
1
Salivary Gland Neoplasm Duct
1
Primary Dysautonomias
1
Patient Compliance
1
PSA Level Greater Than Two
1
Newly Diagnosed Oligometastatic Prostate Cancer
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Leukemia
1
Kidney Diseases
1
Hypertension
1
Hormone Sensitive Prostate Cancer
1
Hereditary Sensory and Autonomic Neuropathies
1
HER2-positive Breast Cancer
1
Granulosa cell tumor of the ovary
1
Carcinoma, Non-Small-Cell Lung
1
Adenocarcinoma
1
Interventions
Sunitinib
2
spartalizumab
1
pembrolizumab
1
palbociclib
1
enzalutamide
1
bicalutamide
1
avelumab
1
aldesleukin
1
Specimen Handling
1
Receptors, Androgen
1
Leuprolide
1
Interleukin-2
1
Health Information Exchange
1
Goserelin
1
Flutamide
1
Blood Specimen Collection
1
Axitinib
1
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Kidney Diseases
×
Leuprolide
×
1 year
×
Clear all
NCT05700903
2026-03-02
ARCH
University of Colorado, Denver
Phase 4
Completed
10 enrolled